Usefulness of thrombosis and inflammation biomarkers in chronic thromboembolic pulmonary hypertension—sampling plasma and surgical specimens

Skoro-Sajer, Nika; Gerges, Christian; Gerges, Mario; Panzenböck, Adelheid; Jakowitsch, Johannes; Kurz, Annabella; Taghavi, Shahrokh; Sadushi-Koliçi, Roela; Campean, Ioana A; Klepetko, Walter; Celermajer, David S.; Lang, Irene

doi:10.1016/j.healun.2018.04.003

Cited by 26 publications

(22 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our review indicated that although various biomarker reports for CTEPH have been published, the majority of these have studied small numbers of patients or has been 24 NA NA NA -Inflammation IL-1b 31,32 NA ---IL-6 [29][30][31] NA þ þ þ IL-8 [28][29][30][31] NA þ þ þ IL- 10 28,29,31 NA þ þ TNF-a 12,29,32 NA þ þ CRP 12,19,21,28,34 þ þ þ þ MCP-1 12,28,32 NA NA þ NA RDW [51][52][53] þ þ þ þ RAGE 38,39 NA NA þ HMGB1 38,39 NA NA NA NA CXCL13 45 NA þ -IP limited to retrospective studies. Some biomarkers that have performed well to date will need to be validated in larger patient populations.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating biomarkers in chronic thromboembolic pulmonary hypertension

Zhang

Pang

et al. 2019

Pulm. circ.

View full text Add to dashboard Cite

Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious condition characterized with chronic organized thrombi that obstruct the pulmonary vessels, leading to pulmonary hypertension (PH) and ultimately right heart failure. Although CTEPH is the only form of PH that can be cured with surgical intervention, not all patients with CTEPH will be deemed operable. Some CTEPH patients still have a poor prognosis. Therefore, the determination of diagnostic and prognostic biomarkers of CTEPH is of great importance for the early intervention to improve prognosis of patients with CTEPH. Several markers related to multiple mechanisms of CTEPH have been recently identified as circulating diagnostic and prognostic biomarkers in these patients. However, the existing literature review of biomarkers of CTEPH is relatively sparse. In this article, we review recent advances in circulating biomarkers of CTEPH and describe future applications of these biomarkers in the management of CTEPH.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The results showed that D-dimer and CRP levels both were the independent predictors of clinical outcome, which decreased distinctively after PEA. 19 Kolk et al. developed a diagnostic model for ruling out CTEPH in symptomatic patients after acute PE.…”

Section: C-reactive Proteinmentioning

confidence: 99%

Circulating biomarkers in chronic thromboembolic pulmonary hypertension

Zhang

Pang

et al. 2019

Pulm. circ.

View full text Add to dashboard Cite

show abstract

“…It is known that DD levels correlate with deep vein thrombosis (DVT) [2,3] and pulmonary thromboembolism [4][5][6], and that they might be a marker of CVST. DD levels are closely, strongly and positively related to the clinical status of DVT [2,7] and some findings have suggested that a high plasma DD level during the course of acute stroke (initially normal) can help detect DVT on duplex venous ultrasonography [8].…”

Section: Clinical Rationale For the Studymentioning

confidence: 99%

Cerebral venous and sinus thrombosis diagnosis: preliminary study of clinical picture and D-dimer concentration correlation

Domitrz

Sadowski

Domitrz

et al. 2020

Neurol Neurochir Pol.

View full text Add to dashboard Cite

Aim of the study. We investigated whether D-dimer (DD) concentration is elevated in cerebral venous and sinus thrombosis (CVST), as has been reported in the literature. Clinical rationale for the study. CVST is a disease with variable clinical presentations and a challenging diagnosis. We looked into whether D-dimer concentration might be an indicator of CVST, and the need for neuroimaging tests correlated with clinical factors. Materials and methods. We included all consecutive patients (mean age 41.6 years) with CVST treated in our neurology department from 2014 to 2018 whose DD levels had been measured. DD concentrations were categorised as normal (≤ 0.5 μg/ml) or elevated (> 0.5 μg/ml). Appropriate imaging confirmed the diagnosis of CVST. The results were compared to those of a control group consisting of 22 age-and sex-matched patients (mean age 40 years) with a diagnosis of primary headache (tension type or migraine) hospitalised to exclude secondary causes. Results. In 20 patients in the CVST study group, median level of DD was 1.0 + 0.57 μg/ml (range 0.19-2.45 μg/ml), compared to the control group's mean DD level of 0.50 + 0.45 μg/ml (range 0.15-1.73 μg/ml), with p < 0.005. Higher DD levels were associated with complications of the disease and fatal course (p < 0.005). One female and one male patient died because of CVST with DD levels of (respectively) 2.45 and 1.80 μg/ml-the two highest concentrations in our study group. Conclusions and clinical implications. DD concentration, especially in headache patients, may be a factor to predict CVST and an indicator for further diagnostic procedures with venography. But in clinical practice, low levels of DD cannot be taken to exclude CVST.

show abstract

“…Plasminogen activator inbibitor-1 was upregulated in the endothelial cells lining the thrombus in humans (60). Furthermore, a prothrombotic milieu, evidenced by elevated levels of von Willebrand Factor and C-reactive protein is associated with CTEPH in humans (60) and CTEPH severity and prognosis correlate with circulating D-dimer levels (61). These conditions are generally difficult to mimic in animal models.…”

Section: Large Animal Models Of Ctephmentioning

confidence: 99%

Chronic Thromboembolic Pulmonary Hypertension – What Have We Learned From Large Animal Models

Stam

Clauß²,

Taverne

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Chronic thrombo-embolic pulmonary hypertension (CTEPH) develops in a subset of patients after acute pulmonary embolism. In CTEPH, pulmonary vascular resistance, which is initially elevated due to the obstructions in the larger pulmonary arteries, is further increased by pulmonary microvascular remodeling. The increased afterload of the right ventricle (RV) leads to RV dilation and hypertrophy. This RV remodeling predisposes to arrhythmogenesis and RV failure. Yet, mechanisms involved in pulmonary microvascular remodeling, processes underlying the RV structural and functional adaptability in CTEPH as well as determinants of the susceptibility to arrhythmias such as atrial fibrillation in the context of CTEPH remain incompletely understood. Several large animal models with critical clinical features of human CTEPH and subsequent RV remodeling have relatively recently been developed in swine, sheep, and dogs. In this review we will discuss the current knowledge on the processes underlying development and progression of CTEPH, and on how animal models can help enlarge understanding of these processes.

show abstract

Usefulness of thrombosis and inflammation biomarkers in chronic thromboembolic pulmonary hypertension—sampling plasma and surgical specimens

Cited by 26 publications

References 22 publications

Circulating biomarkers in chronic thromboembolic pulmonary hypertension

Circulating biomarkers in chronic thromboembolic pulmonary hypertension

Cerebral venous and sinus thrombosis diagnosis: preliminary study of clinical picture and D-dimer concentration correlation

Chronic Thromboembolic Pulmonary Hypertension – What Have We Learned From Large Animal Models

Contact Info

Product

Resources

About